In preclinical investigation, CJC-1295 and Ipamorelin represent a prominent dual-receptor approach to studying the somatotropic axis. CJC-1295 functions as a long-acting growth-hormone-releasing hormone (GHRH) analog that sustains GH and downstream IGF-1 levels for tissue repair research, while Ipamorelin acts as a highly selective growth hormone secretagogue receptor (GHSR-1a) agonist.
In preclinical investigation, CJC-1295 and Ipamorelin represent a prominent dual-receptor approach to studying the somatotropic axis. CJC-1295 functions as a long-acting growth-hormone-releasing hormone (GHRH) analog that sustains GH and downstream IGF-1 levels for tissue repair research, while Ipamorelin acts as a highly selective growth hormone secretagogue receptor (GHSR-1a) agonist.
The somatotropic axis regulates cellular proliferation, protein synthesis, substrate utilization, and somatic growth through a tightly controlled neuroendocrine cascade. Central to this system are growth hormone-releasing hormone (GHRH) and ghrelin (or growth hormone secretagogues), which bind to distinct GPCR (G-protein coupled receptor) targets on pituitary somatotropes. Combining GHRH analogs with selective ghrelin receptor agonists has emerged as a major focus in laboratory research aimed at elucidating dual signal amplification pathways.
When investigating CJC-1295 and Ipamorelin research, scientists examine how simultaneous activation of the GHRH receptor (GHRHR) and the growth hormone secretagogue receptor 1a (GHSR-1a) produces a synergistic elevation in growth hormone (GH) transcription and exocytosis. Unlike single-agent models, co-administration protocols allow researchers to map complementary intracellular second-messenger cascades without inducing premature receptor desensitization or unphysiological stress-axis stimulation.
CJC-1295 is a synthetic 29-amino-acid peptide derived from human GHRH (1-29), modified at positions 2, 8, 15, and 27 to increase enzymatic stability against dipeptidyl peptidase-IV (DPP-IV) degradation. In preclinical models, CJC-1295 acts as a GHRH analog studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. By binding specifically to GHRHR on anterior pituitary somatotropes, it stimulates the Gs alpha subunit pathway, increasing intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA).
Laboratory formulations of CJC-1295 are primarily evaluated in two variants: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (often referred to as Modified GRF 1-29). The inclusion of the maleimidopropionic acid-based DAC moiety enables covalent binding to endogenous serum albumin in animal models, extending the elimination half-life from approximately 30 minutes to over 6 days. Researchers select CJC-1295 No DAC when pulsatile signaling profiles mimicking endogenous GHRH releases are required for in vitro or animal models.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a potent and highly selective agonist of the growth hormone secretagogue receptor 1a (GHSR-1a). Unlike early-generation ghrelin peptidomimetics, Ipamorelin binds to GHSR-1a to activate the Gq/11 protein pathway, triggering phospholipase C (PLC) activation, inositol trisphosphate (IP3) production, and transient intracellular calcium influx from the endoplasmic reticulum.
A critical distinction highlighted in comparative receptor profiling is Ipamorelin’s receptor selectivity. Preclinical bioassays confirm that Ipamorelin does not induce significant transcription or secretion of adrenocorticotropic hormone (ACTH), cortisol, aldosterone, or prolactin, even at elevated concentrations. This selectivity profile allows researchers to isolate GH-mediated cellular events without confounding interference from stress hormone cascades.
The molecular rationale for evaluating CJC-1295 and Ipamorelin in tandem relies on receptor cross-talk at the somatotrope level. GHRH signaling via CJC-1295 recruits the cAMP/PKA axis, which enhances transcription of the GH gene and increases the pool of readily releasable GH secretory vesicles. Concurrently, Ipamorelin signals via the IP3/DAG/calcium pathway, promoting vesicle fusion with the plasma membrane and exocytotic release.
In vitro studies demonstrate that concurrent stimulation of GHRHR and GHSR-1a yields a supra-additive response. PKA-mediated phosphorylation enhances the sensitivity of voltage-gated calcium channels opened by GHSR-1a signaling. As a result, the combined release profile exceeds the arithmetic sum of each peptide tested independently, providing researchers with an efficient model for studying maximum physiological secretory capacity.
Pulsatile or sustained elevations in circulating GH directly stimulate hepatic transcription of Insulin-like Growth Factor 1 (IGF-1), as well as local tissue IGF-1 expression in skeletal muscle, articular cartilage, and tendon fibroblasts. In murine and cell culture models, the CJC-1295 and Ipamorelin pairing is frequently utilized to study autocrine and paracrine tissue repair mechanisms.
Preclinical data indicate that sustained downstream IGF-1 signaling upregulates the PI3K/Akt/mTOR pathway, driving amino acid transport, myofibrillar protein synthesis, and extracellular matrix remodeling. Researchers investigating cellular senescence, wound healing assays, and myotube hypertrophy utilize these compounds to measure mRNA transcript levels of collagen types I and III, as well as markers of satellite cell activation in vitro.
To ensure reproducible assay results, lyophilized research peptides must be handled under strict laboratory conditions. CJC-1295 and Ipamorelin are provided as sterile, lyophilized powders that require reconstitution with bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection, depending on experimental design.
Upon receipt, lyophilized vials should be stored at -20°C for short-term preservation or -80°C for long-term storage. Following reconstitution with an appropriate laboratory solvent, stock solutions should be aliquoted into single-use microcentrifuge tubes to prevent degradation from repeated freeze-thaw cycles. Reconstituted solutions maintain stability at 2°C to 8°C for up to 30 days when protected from light and physical agitation.
When designing somatotropic signaling protocols, investigators often compare CJC-1295 and Ipamorelin against alternative peptide combinations within our catalog of research peptides. For instance, Tesamorelin exhibits a distinct transactivation profile focused heavily on visceral adipocyte lipolysis, whereas Sermorelin possesses a shorter biological half-life due to rapid cleavage by native peptidases. Similarly, earlier GHRPs like GHRP-6 offer robust secretagogue action but demonstrate off-target binding to ghrelin receptors in the central nervous system, which stimulates appetite pathways and cortisol release.
The table below summarizes the receptor targets and kinetic distinctions across key secretagogues evaluated in laboratory research:
Experimental reproducibility requires research reagents with verified chemical composition, accurate peptide mass, and minimal contamination. Low-purity compounds or residual synthesis reagents introduce confounding variables in cell culture assays and preclinical models.
PX1 Research enforces stringent analytical testing protocols for every batch. Products undergo High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity (>99%) and Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-TOF MS) or ESI-MS to confirm exact molecular weight. Additionally, analytical testing includes chromogenic LAL assays to ensure endotoxin levels remain strictly below <0.01 EU/mg, protecting cell culture systems from lipopolysaccharide-induced inflammatory artifacts.
Securing high-purity compounds is essential for institutional research laboratories and private facilities executing advanced metabolic or cellular models. PX1 Research manufactures research-grade peptides in US-based, GMP-compliant facilities adhering to ISO 17025 laboratory quality standards.
Every lot of peptide is accompanied by a downloadable, lot-specific Certificate of Analysis (COA) displaying full RP-HPLC chromatograms and mass spectra. Orders ship same-day (Monday through Friday) directly from facility hubs in California and Arizona. Institutional buyers seeking bulk volume for long-term animal studies or high-throughput assay platforms can explore customized supply contracts through our wholesale laboratory portal.
What is the primary mechanism of action in CJC-1295 and Ipamorelin research?
CJC-1295 acts as a GHRH analog that binds to pituitary GHRH receptors to activate the cAMP/PKA pathway, while Ipamorelin acts as a selective GHSR-1a agonist triggering the IP3/DAG calcium influx pathway. Together, they produce a synergistic increase in growth hormone transcription and secretion in preclinical models.
How does CJC-1295 No DAC differ from CJC-1295 with DAC?
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex moiety, resulting in a short half-life (~30 minutes) that mimics natural pulsatile GH release. CJC-1295 with DAC covalently binds serum albumin, extending its biological half-life to several days and sustaining continuous GH/IGF-1 levels.
What are the recommended reconstitution solvent parameters for laboratory assays?
Lyophilized CJC-1295 and Ipamorelin are typically reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) for multi-use laboratory sampling or sterile 0.9% sodium chloride for acute in vitro assays where preservatives must be avoided.
Does Ipamorelin stimulate off-target hormonal axes such as cortisol or prolactin?
No. In vitro and animal studies demonstrate that Ipamorelin is highly selective for GHSR-1a and does not significantly alter ACTH, cortisol, aldosterone, or prolactin secretion, unlike non-selective secretagogues such as GHRP-2 or GHRP-6.
What endotoxin limits are verified on PX1 Research COAs?
PX1 Research verifies that all analytical-grade peptide lots maintain endotoxin levels strictly below <0.01 EU/mg using kinetic chromogenic LAL testing, ensuring suitability for sensitive cell cultures and in vivo animal models.
Where can researchers access analytical verification data for CJC-1295 and Ipamorelin?
Lot-specific Certificates of Analysis (COAs), including raw RP-HPLC chromatograms and mass spectrometry mass-to-charge reports, are publicly accessible on the PX1 [research hub](/research) and individual product pages.
How should reconstituted peptide solutions be stored to prevent degradation?
Reconstituted stock solutions should be stored at 2°C to 8°C for short-term use (up to 30 days) or aliquoted into sterile microtubes and stored at -80°C to prevent freeze-thaw degradation.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.